The U.S. Food and Drug Administration approved Eli Lilly’s Lyumjev (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), a new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes.

Eli Lilly and Sanofi, two of the largest manufacturers of insulin products, are responding to those in need of such life-saving drugs during the COVID-19 pandemic with programs that will provide continued access to insulin medication.

A smart insulin device under development could revolutionize how glucose levels are monitored in diabetes patients and deliver insulin doses when necessary.

CVS Health Corp.’s pharmacy benefit management (PBM) unit is launching a new program under which employers and insurers will be able to offer diabetes drugs, including insulin, at no out-of-pocket costs to their members.

Eli Lilly’s senior vice president and chief financial officer Josh Smiley announced plans for the Indianapolis-based pharmaceutical company to spend from $1 billion to $5 billion each quarter during 2020 to bolster the drug manufacturer’s product pipeline.

Eli Lilly and Co. plans to sell two versions of insulin products at half their current U.S. list prices, eight months after the drug manufacturer started selling a half-priced version of the widely used Humalog injection.

The U.S. Food and Drug Administration approved Novo Nordisk’s Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.

Novo Nordisk will offer free, one-time supply of insulin to people in immediate need and at risk of rationing the medication.

Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.

The U.S. Food and Drug Administration approved an expanded indication for Sanofi’s Toujeo (insulin glargine injection) for blood sugar control in adult and pediatric patients who are ages 6 years and older. The expanded indication approved by the FDA applies to both type 1 and 2 diabetes. Previously, Toujeo was U.S.-approved only for adults aged 18 years and older.